What are the factors associated with long‐term glycaemic control in patients with type 2 diabetes and elevated glycated haemoglobin (≥7.0%) at initiation of second‐line therapy? Results from the DISCOVER study-Reference-Cited by-同舟云学术

What are the factors associated with long‐term glycaemic control in patients with type 2 diabetes and elevated glycated haemoglobin (≥7.0%) at initiation of second‐line therapy? Results from the DISCOVER study

Published:2021-08-02 Issue:10 Volume:23 Page:2336-2343
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Bonnet Fabrice¹^ORCID,Chen Hungta²,Cooper Andrew³,Gomes Marίlia B.⁴^ORCID,Ji Linong⁵^ORCID,Leigh Paul³,Ramirez Larisa⁶,Shestakova Marina V.⁷,Shimomura Iichiro⁸,Siddiqui Afrah³,Tang Fengming⁹,Vora Jiten¹⁰,Watada Hirotaka¹¹^ORCID,Khunti Kamlesh¹²^ORCID

Affiliation:

1. Department of Endocrinology Rennes University Hospital, Rennes 1 University Rennes France

2. AstraZeneca Gaithersburg Maryland USA

3. AstraZeneca Cambridge UK

4. Rio de Janeiro State University Rio de Janeiro Brazil

5. Peking University People's Hospital Beijing China

6. AstraZeneca Luton UK

7. Endocrinology Research Center, Diabetes Institute Moscow Russian Federation

8. Graduate School of Medicine Osaka University Osaka Japan

9. Saint Luke's Mid America Heart Institute Kansas City Missouri USA

10. University of Liverpool Liverpool UK

11. Graduate School of Medicine Juntendo University Tokyo Japan